» Articles » PMID: 35677044

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries

Abstract

Background: Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are critical in sustaining long-term protection and therefore may be an important factor when assessing pertussis immunity after vaccination.

Aim: We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries.

Materials And Methods: From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children (7-10y, n=53), adolescents (11-15y, n=66), young adults (20-34y, n=74), and older adults (60-70y, n=75). Memory B cells at baseline, day 28, and 1 year post-vaccination were measured by a pertussis toxin (Ptx), filamentous haemagglutinin (FHA), and pertactin (Prn) specific ELISpot assay. Antibody results measured previously were available for comparison. Furthermore, study participants were distributed into groups based on their baseline memory B cell frequencies, vaccine responses were monitored between these groups.

Results: Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one year post-booster compared to baseline. Highest frequencies at day 28 were found within adolescents (GM: 5, 21, and 13, for Ptx, FHA and Prn, respectively) and lowest within older adults (GM: 2, 9, and 3, respectively). Moderate to strong correlations between memory B cell frequencies at day 28 and antibody concentrations at day 28 and 1 year were observed for Prn. Memory B cell frequencies > 1 per 100,000 PBMCs at baseline were associated with significantly higher memory responses after 28 days and 1 year.

Conclusions: An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory B cell activation seems weaker in older adults, which might reflect immunosenescence. Furthermore, the presence of circulating memory B cells at baseline positively affects memory B cell responses. This study was registered at www.clinicaltrialsregister.eu: No. 2016-003678-42.

Citing Articles

Impact of Immunosenescence on Vaccine Immune Responses and Countermeasures.

Chen L, Shao C, Li J, Zhu F Vaccines (Basel). 2024; 12(11).

PMID: 39591191 PMC: 11598585. DOI: 10.3390/vaccines12111289.


Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.

Gillard J, Suffiotti M, Brazda P, Venkatasubramanian P, Versteegen P, de Jonge M Nat Commun. 2024; 15(1):2133.

PMID: 38459022 PMC: 10923912. DOI: 10.1038/s41467-024-46560-w.


Booster Immunization Improves Memory B Cell Responses in Older Adults Unresponsive to Primary SARS-CoV-2 Immunization.

Verheul M, Nijhof K, de Zeeuw-Brouwer M, Duijm G, Ten Hulscher H, de Rond L Vaccines (Basel). 2023; 11(7).

PMID: 37515012 PMC: 10384172. DOI: 10.3390/vaccines11071196.


Effect of immunization during pregnancy and pre-existing immunity on diphtheria-tetanus-acellular pertussis vaccine responses in infants.

Knuutila A, Barkoff A, Ivaska L, Tenhu E, Terasjarvi J, van Gageldonk P Emerg Microbes Infect. 2023; 12(1):2204146.

PMID: 37060181 PMC: 10161941. DOI: 10.1080/22221751.2023.2204146.


Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection.

Knuutila A, Dalby T, Ahvenainen N, Barkoff A, Jorgensen C, Fuursted K Emerg Microbes Infect. 2023; 12(1):e2174782.

PMID: 36715361 PMC: 9936998. DOI: 10.1080/22221751.2023.2174782.


References
1.
Barkoff A, Mertsola J, Pierard D, Dalby T, Hoegh S, Guillot S . Pertactin-deficient isolates: evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill. 2019; 24(7). PMC: 6381657. DOI: 10.2807/1560-7917.ES.2019.24.7.1700832. View

2.
Diks A, Versteegen P, Teodosio C, Groenland R, de Mooij B, Buisman A . Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination. Vaccines (Basel). 2022; 10(2). PMC: 8878388. DOI: 10.3390/vaccines10020136. View

3.
Klein N, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R . Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013; 131(6):e1716-22. DOI: 10.1542/peds.2012-3836. View

4.
Cherry J . Pertussis: challenges today and for the future. PLoS Pathog. 2013; 9(7):e1003418. PMC: 3723573. DOI: 10.1371/journal.ppat.1003418. View

5.
Kurosaki T, Kometani K, Ise W . Memory B cells. Nat Rev Immunol. 2015; 15(3):149-59. DOI: 10.1038/nri3802. View